Characteristics and outcome of octogenarian versus young patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) treated with ketoconazole.

被引：0
|
作者：
Sinibaldi, Victoria J.
Dadon-Nachum, Michal
Gottfried, Maya
Maimon, Natalie
Dovrish, Zamir
Peer, Avivit
Neumann, Avivit
Sella, Avishay
Kovel, Svetlana
Carducci, Michael Anthony
Eisenberger, Mario A.
Kejzman, Daniel
机构：
[1] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[2] Meir Med Ctr, Dept Oncol, Kefar Sava, Israel
[3] Meir Med Ctr, Lung Canc Unit, Kefar Sava, Israel
[4] Tel Aviv Univ, Sackler Sch Med, Meir Med Ctr, Genitourinary Oncol Serv,Div Oncol, Kefar Sava, Israel
[5] Meir Med Ctr, Dept Internal Med D, Kefar Sava, Israel
[6] Rambam Hlth Care Campus, Haifa, Israel
[7] Rambam Med Ctr, Dept Oncol, Haifa, Israel
[8] Assaf Harofeh Med Ctr, IL-70300 Zerifin, Israel
[9] Asaf Harofe Med Ctr, Dept Oncol, Zerifin, Israel
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 04期
关键词：
D O I：
10.1200/jco.2014.32.4_suppl.256
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
256
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Trends in prescribing preferences (PPrefs) of US-based oncologists for patients (Pts) with metastatic castrate-resistant prostate cancer (mCRPC) following docetaxel (DO).
    Ryan, Charles J.
    Kim, Won
    Buettner, Arden
    Britton, Susan Lynne
    Lankford, Maria L.
    Neely, Doug B.
    Green, Mark R.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [32] Antimitotic agents for the treatment of patients with metastatic castrate-resistant prostate cancer
    Wissing, Michel D.
    van Diest, Paul J.
    van der Wall, Elsken
    Gelderblom, Hans
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (05) : 635 - 661
  • [33] Novel Therapies for Metastatic Castrate-Resistant Prostate Cancer
    Dayyani, Farshid
    Gallick, Gary E.
    Logothetis, Christopher J.
    Corn, Paul G.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (22): : 1665 - 1675
  • [34] Metastatic Castrate-Resistant Prostate Cancer Practical Review
    Moeller, Abby
    Cookson, Michael
    Patel, Sanjay G.
    PHYSICIAN ASSISTANT CLINICS, 2018, 3 (01) : 11 - +
  • [35] Cabazitaxel for octogenarian patients with metastatic castration-resistant prostate cancer (MCRPC)
    Tralongo, P.
    Bordonaro, S.
    Di Lorenzo, G.
    Borsellino, N.
    Facchini, G.
    Rossetti, S.
    Martelli, V.
    Longo, V.
    Tralongo, A. C.
    Caspani, F.
    Tuzi, A.
    Spada, M.
    Calvani, N.
    Carlini, P.
    De Giorgi, U. F. F.
    ANNALS OF ONCOLOGY, 2019, 30
  • [36] Statin use and outcome in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated in the TROPIC trial
    Lorente, D.
    De Velasco Oria, G. A.
    Carles, J.
    Gillessen, S.
    Fizazi, K.
    Joshua, A.
    Eisenberger, M.
    Sartor, O.
    de Bono, J. S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [37] Seven Years of Clinical Experience Outcome Review on Radium 223 Therapy In Bone Metastatic Castrate-resistant Prostate Cancer (mCRPC)
    Cantinho-Lopes, M.
    Pena, H.
    Filipe, P.
    Mansinho, A.
    Fernandes, I.
    Costa, L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S400 - S400
  • [38] Analysis of the prognostic significance of circulating tumor DNA (ctDNA) in metastatic castrate-resistant prostate cancer (mCRPC)
    Shaya, Justin
    Randall, James Michael
    Millard, Frederick E.
    Kurzrock, Razelle
    Parsons, J. Kellogg
    Tamayo, Pablo
    McKay, Rana R.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [39] Cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).
    Karzai, Fatima
    Madan, Ravi Amrit
    Theoret, Marc Robert
    Arlen, Philip M.
    Dawson, Nancy Ann
    Rosner, Inger L.
    McLeod, David G.
    Wright, John Joseph
    Cordes, Lisa M.
    Couvillon, Anna
    Chun, Guinevere
    Harold, Nancy
    Steinberg, Seth M.
    Trepel, Jane B.
    Price, Douglas K.
    Gulley, James L.
    Figg, William Douglas
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [40] Use of low-dose, weekly carboplatin in men with metastatic castrate-resistant prostate cancer (mCRPC).
    O'Leary-Kelly, Meghan
    Gao, Dexiang
    Weisdack, Sarah
    Lam, Elaine Tat
    Bernard, Brandon David
    Flaig, Thomas W.
    Kessler, Elizabeth Riley
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
12345